🔍

Medicamen Biotech Limited (MEDICAMEQ)

📊 NSE: MEDICAMEQ 🏢 Pharmaceuticals - Indian - Formulations 📅 Last Updated: 12/14/2025 9:45

📢 Recent Corporate Announcements

Medicamen Biotech Submits FY26 BRSR & Annual Report; 33rd AGM Set for Sep 26, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 03 Sep 2026, 05:34 PM

Medicamen Biotech Limited has submitted its Integrated Annual Report and Business Responsibility and Sustainability Report (BRSR) for FY 2025-26. The company announced its 33rd Annual General Meeting (AGM) will be held on September 26, 2026, via video conferencing. The BRSR disclosures highlight that exports generate approximately 80% of total revenue across 35+ international markets, supported by 3 national manufacturing facilities and 405 permanent employees.

33rd AGM scheduled for September 26, 2026, via Video Conferencing / OAVM.
FY26 total turnover reported in BRSR stood at Rs 178.85 cr with PAT of Rs 9.41 cr.
Exports contributed 80% of total sales, covering over 35 countries across Asia, Africa, and Latin America.
Operates 3 manufacturing facilities (Bhiwadi and Haridwar Unit I & II) with 405 permanent employees.

💡 Shareholders may review the FY26 Integrated Annual Report and vote on AGM resolutions ahead of the meeting on September 26, 2026.

Medicamen Biotech Submits FY26 Business Responsibility and Sustainability Report

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 03 Sep 2026, 05:32 PM

Medicamen Biotech Limited has submitted its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26 as part of its Annual Report. The report discloses standalone annual turnover of ₹178.85 crore and profit after tax of ₹9.41 crore. Exports accounted for approximately 80% of total turnover across more than 35 countries. The company operated 3 manufacturing facilities (Bhiwadi and Haridwar) with 405 permanent employees and reported zero product recalls or safety penalties during the fiscal year.

Annual turnover reported at ₹178.85 crore with Profit After Tax of ₹9.41 crore for FY 2025-26
Exports contributed 80% of total turnover, covering more than 35 international destinations
CSR expenditure stood at ₹25.20 lakh against a required spend of ₹31.33 lakh, with ₹6.13 lakh unspent transferred as per rules
Workforce comprised 405 permanent employees and 255 non-permanent workers across 3 manufacturing locations
Zero product recalls (voluntary or forced) and nil regulatory penalties reported for the fiscal year

💡 Track upcoming quarterly financial performance (Q2 FY27) and updates regarding regulatory approvals (US-FDA/EU) for the oncology formulation facilities.

Medicamen Biotech Sets Sept 19, 2026 Record Date for FY26 Final Dividend and 33rd AGM

🟡 NEUTRAL ⭐ 3/10

DIVIDEND 📅 18 Aug 2026, 01:31 PM

Medicamen Biotech Limited has announced the record date and book closure period for its 33rd Annual General Meeting (AGM) and the payment of a final dividend for FY 2025-26. The record date to determine shareholder dividend eligibility is fixed as Saturday, September 19, 2026. The Register of Members and Share Transfer Books will be closed from Sunday, September 20, 2026 to Saturday, September 26, 2026 (both days inclusive). The final dividend payout remains subject to shareholder approval at the upcoming AGM.

Record date fixed as Saturday, September 19, 2026 for dividend entitlement
Book closure period scheduled from September 20, 2026 to September 26, 2026
Dividend payment is subject to approval at the 33rd Annual General Meeting
Applies to equity shares on both BSE (531146) and NSE (MEDICAMEQ)

💡 Investors seeking dividend eligibility must hold shares before the September 19, 2026 record date; watch for the exact AGM outcome and dividend payout timelines.

Medicamen Biotech Announces Closure of Register of Members and Share Transfer Books

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 14 Aug 2026, 04:13 PM

Medicamen Biotech Limited has notified the stock exchange regarding the closure of its Register of Members and Share Transfer Books. This is a standard procedural requirement typically conducted annually in preparation for the company's Annual General Meeting (AGM). The filing is administrative in nature and does not disclose specific financial impact or upcoming dividend amounts at this stage.

Announcement dated August 14, 2026, regarding book closure
Procedural compliance for the Register of Members and Share Transfer Books
Company maintains a Market Cap of ₹15,226 Cr as per latest context
TTM Revenue stands at ₹9,516 Cr with a PAT of ₹381 Cr

💡 Investors should monitor for the formal Annual General Meeting (AGM) notice to confirm the record date and any proposed dividend or corporate actions.

Medicamen Biotech Sets September 19, 2026, as Record Date for Dividend

🟡 NEUTRAL ⭐ 3/10

DIVIDEND 📅 14 Aug 2026, 04:10 PM

Medicamen Biotech Limited has officially designated September 19, 2026, as the record date to determine shareholder eligibility for a dividend. This announcement follows a period where the company reported a TTM PAT of ₹381 Cr and TTM revenue of ₹9,516 Cr. The stock has faced significant pressure, with a 12-month price return of -31.9%. This filing is a routine procedural step in the dividend distribution process.

Record date for dividend eligibility is fixed for September 19, 2026
Announcement provides a 36-day lead time from the notice date of August 14, 2026
Company maintains a TTM revenue of ₹9,516 Cr despite recent stock price volatility
Market capitalization stands at ₹15,226 Cr with a P/E ratio of 39.9

💡 Investors should monitor the ex-dividend date, which typically falls one business day prior to the record date, to ensure they are eligible for the payout.

Medicamen Biotech Q1 Net Profit Up 15% YoY to ₹1.85 Cr; ₹1 Dividend Recommended

🟡 NEUTRAL ⭐ 6/10

EARNINGS 📅 14 Aug 2026, 03:39 PM

Medicamen Biotech reported a consolidated total revenue of ₹48.76 Cr for Q1 FY27, a 12% increase over the ₹43.52 Cr reported in the same quarter last year. Net profit grew 15% YoY to ₹1.85 Cr, although it saw a sharp sequential decline from ₹4.45 Cr in Q4 FY26. The board recommended a final dividend of ₹1.00 per share (10% of face value) for FY26. Notably, the company disclosed paying ₹2.22 lakh in total fines to BSE and NSE for non-compliance regarding the composition of its Nomination and Remuneration Committee.

Consolidated Total Revenue reached ₹48.76 Cr, up 12.1% from ₹43.52 Cr in Q1 FY26.
Consolidated Net Profit stood at ₹1.85 Cr, a 15.3% increase compared to ₹1.60 Cr in the year-ago period.
Proposed a final dividend of ₹1.00 per equity share (10%) for the financial year 2025-26.
Paid regulatory fines of ₹1,10,920 each to BSE and NSE for non-compliance with NRC composition rules.
Consolidated EPS for the quarter improved to ₹1.36 from ₹1.18 in the corresponding previous quarter.

💡 Monitor the oncology segment's progress toward its breakeven target and track if the company can stabilize operating margins, which showed significant sequential volatility this quarter.

June 30, 2026: Medicamen Biotech confirms routine SEBI Regulation 74(5) compliance

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 28 Jul 2026, 12:29 PM

Medicamen Biotech Limited has submitted its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The filing confirms that share certificates received for dematerialization during the quarter ended June 30, 2026, were processed within the mandated 30-day period. The company verified that these securities are listed on the BSE and NSE, and physical certificates were mutilated and cancelled as per protocol. This is a standard administrative procedure with no impact on the company's financial performance.

Compliance certificate issued for the quarter ended June 30, 2026
Dematerialization requests processed and records updated within 30 days of receipt
Confirmation that securities are listed on BSE (Code: 531146) and NSE (Code: MEDICAMEQ)
Physical certificates mutilated and cancelled after due verification

💡 This is a routine administrative filing. Investors should focus on the company's upcoming quarterly earnings report for material updates on operational and financial performance.

Medicamen Biotech Announces Trading Window Closure from July 1, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 24 Jun 2026, 04:23 PM

Medicamen Biotech Limited has informed the exchanges that its trading window will be closed starting July 1, 2026, for all designated persons and their relatives. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the Q1 FY2026-27 financial results. The window will remain closed until 48 hours after the un-audited financial results for the quarter ending June 30, 2026, are declared. The specific date for the board meeting to approve these results will be announced at a later date.

Trading window closure begins on July 1, 2026, for all Directors and Designated Persons.
Closure is related to the un-audited financial results for the quarter ending June 30, 2026.
The window will reopen 48 hours after the official declaration of the financial results.
The date for the Board of Directors meeting to approve results is yet to be announced.

💡 This is a routine regulatory filing and does not require any immediate action. Investors should monitor for the upcoming announcement of the board meeting date to review the company's quarterly performance.

Medicamen Biotech Promoter Shivalik Rasayan Discloses No Share Encumbrance for FY26

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 22 Jun 2026, 07:13 PM

Shivalik Rasayan Limited, the promoter of Medicamen Biotech Limited, has submitted its annual disclosure for the financial year ended March 31, 2026. Under Regulation 31(4) of the SEBI (SAST) Regulations, the promoter confirmed that they have not made any encumbrance, directly or indirectly, on their shareholding during the period. This is a standard annual compliance requirement to ensure transparency regarding promoter share pledges and confirms that promoter shares remain unencumbered.

Promoter Shivalik Rasayan Limited filed the annual disclosure under Regulation 31(4) of SEBI (SAST) Regulations.
The disclosure confirms no encumbrance was created on promoter shares for the year ended March 31, 2026.
The filing was submitted to both BSE and NSE on April 7, 2026, as per statutory timelines.

💡 No immediate action is required as this is a routine regulatory filing confirming the absence of share pledges by the promoter.

Medicamen Biotech Reports Zero Deviation in Utilization of ₹53.57 Cr Preferential Issue Funds

🟢 POSITIVE ⭐ 6/10

REGULATORY 📅 28 May 2026, 12:14 PM

Medicamen Biotech Limited has submitted its statement of deviation for the quarter and year ended March 31, 2026, regarding funds raised via a preferential issue. The company raised approximately ₹53.57 crore on April 24, 2025, to fund drug development, capital expenditure, and domestic expansion. As of March 31, 2026, the company has successfully utilized ₹29.30 crore of the total proceeds. The Audit Committee has confirmed that there are no deviations or variations in the utilization of these funds from the objects originally stated.

Total funds raised through preferential issue on April 24, 2025, amounted to ₹53,56,82,326.93.
Cumulative funds utilized for stated objects as of March 31, 2026, stand at ₹29,29,82,326.93.
Audit Committee confirmed zero deviation or variation from the original objects of the issue.
Funds are being deployed for drug development of 50 SKUs for regulated markets and facility upgrades.

💡 Investors should view this as a positive sign of management's adherence to capital allocation plans. Monitor the progress of the 50 SKU drug development pipeline as the remaining ₹24.27 crore is deployed.

Medicamen Biotech Approves FY26 Results, Recommends ₹1.00 Final Dividend

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 27 May 2026, 03:44 PM

Medicamen Biotech Limited has announced its audited financial results for the fiscal year ended March 31, 2026. The Board of Directors has recommended a final dividend of ₹1.00 per equity share (10% of face value), subject to shareholder approval. The company also appointed new Cost and Internal Auditors for the 2026-27 fiscal year to strengthen its compliance framework. Importantly, the statutory auditors have issued an unmodified opinion on the financial statements, indicating no major accounting discrepancies.

Recommended a final dividend of ₹1.00 per equity share of face value ₹10 for the financial year ended March 31, 2026.
Statutory auditors M/s Rai Qimat & Associates issued an unmodified opinion on both standalone and consolidated financial results.
Appointed M/s SPB & Co as Cost Auditor and M/s Cheena & Associates as Internal Auditor for the financial year 2026-27.
The Board meeting commenced at 01:30 PM and concluded at 03:00 PM on May 27, 2026.

💡 Investors should review the detailed profit and loss statements to assess operational growth. The dividend recommendation suggests a stable financial position and commitment to shareholder returns.

Medicamen Biotech Announces Trading Window Closure from April 1, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 30 Mar 2026, 12:57 PM

Medicamen Biotech Limited has officially announced the closure of its trading window for all designated persons starting April 1, 2026. This move is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the company's upcoming financial disclosures. The closure will remain in effect until 48 hours after the declaration of the Audited Financial Results for the quarter and year ending March 31, 2026. This is a standard regulatory procedure to ensure market integrity before sensitive financial data is released.

Trading window for designated persons to close effective April 1, 2026.
Closure pertains to the Audited Financial Results for the quarter and year ended March 31, 2026.
The window will reopen 48 hours after the financial results are officially declared to the public.
The restriction applies to all Directors, Designated Persons, and Connected Persons under the company's Code of Conduct.

💡 No immediate action is required as this is a routine regulatory compliance filing. Investors should await the announcement of the board meeting date for the actual Q4 and FY26 earnings release.

Medicamen Biotech Receives NSE Cautionary Letter Over Secretarial Compliance Observations

🟡 NEUTRAL ⭐ 4/10

REGULATORY 📅 21 Feb 2026, 04:51 PM

Medicamen Biotech Limited has received a cautionary letter from the National Stock Exchange (NSE) regarding observations in its Secretarial Compliance Report for the financial year ended March 31, 2025. The communication, received on January 27, 2026, advises the company to be more diligent in adhering to SEBI Listing Regulations to prevent future lapses. The company has clarified that this regulatory warning has no quantifiable impact on its financial or operational activities. This is an administrative warning rather than a financial penalty or suspension.

NSE issued a cautionary letter on January 27, 2026, following secretarial audit observations.
The observations pertain to the Annual Secretarial Compliance Report for the financial year ended March 31, 2025.
The company has been advised to be careful in the future to avoid recurrence of such compliance lapses.
Management confirms there is zero impact on the company's financials, operations, or other activities.

💡 No immediate action is required as the warning is procedural and carries no financial penalty. Investors should monitor future secretarial reports to ensure the company improves its regulatory adherence.

Medicamen Biotech Corrects Retirement Date for Two Independent Directors to Feb 26, 2026

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 18 Feb 2026, 06:04 PM

Medicamen Biotech Limited has issued a corrigendum regarding the retirement of two Independent Directors, Mr. Harish Pande and Mr. Arun Kumar. The company clarified that their term concludes on February 26, 2026, rather than the February 13, 2026 date previously reported. This correction follows a clerical error in the initial intimation. The update ensures regulatory compliance and accurate record-keeping regarding board composition.

Retirement date for Independent Directors Mr. Harish Pande and Mr. Arun Kumar corrected to Feb 26, 2026.
Initial announcement dated Feb 13, 2026, cited an incorrect retirement date due to a clerical error.
The directors will officially cease their roles at the close of business on February 26, 2026.

💡 This is a routine administrative update with no impact on business fundamentals; no specific action is needed.

Medicamen Biotech: Independent Directors Harish Pande and Arun Kumar Complete Terms

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 13 Feb 2026, 04:26 PM

Medicamen Biotech Limited has announced the completion of the terms of two Independent Directors, Mr. Harish Pande and Mr. Arun Kumar, effective February 13, 2026. Both directors have consequently stepped down from their positions in the Audit, Nomination & Remuneration, and Risk Management committees. To ensure a smooth transition, the company had previously appointed Mr. Sham Goel and Mr. Shaival Saurabh as Independent Directors in August 2025. Mr. Sham Goel will now assume the role of Chairman for the Audit and CSR Committees, maintaining continuity in the company's governance structure.

Mr. Harish Pande and Mr. Arun Kumar completed their tenures as Independent Directors on February 13, 2026.
The outgoing directors ceased to be members/chairpersons of five key board committees including Audit and Risk Management.
Successors Mr. Sham Goel and Mr. Shaival Saurabh were pre-appointed in August 2025 and approved by shareholders in September 2025.
Mr. Sham Goel is designated as the new Chairman of the Audit Committee and CSR Committee effective February 13, 2026.

💡 This is a routine management transition due to the completion of fixed terms for independent directors. No immediate action is required as the company has already secured shareholder approval for the successor directors.

View All MEDICAMEQ Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

The company achieved a 28% YoY growth in operating income, reaching INR 179.3 Cr in FY24 compared to INR 140.8 Cr in FY23. Growth is primarily driven by the core formulations segment, while the oncology segment, which started commercial production in January 2022, is yet to reach breakeven, currently weighing on overall profitability.

Geographic Revenue Split

Africa is the dominant region, contributing approximately 70% of total sales. The remaining 30% is derived from the domestic Indian market, including government sector contracts. The company is actively planning expansion into European and USA markets over the medium term to diversify this concentration.

Profitability Margins

Operating margins declined significantly from 18.35% in FY23 to 13.1% in FY24. This 525 basis point drop is attributed to the oncology segment's gestation period. Net Profit After Tax (PAT) fell from INR 14.73 Cr (10.45% margin) in FY23 to INR 9.49 Cr (5.34% margin) in FY24.

EBITDA Margin

Operating EBITDA margin stood at 13.1% for FY24. Management expects margins to recover to the 14-15% range in FY25 as the oncology segment achieves breakeven and capacity utilization improves at the Haridwar plant.

Capital Expenditure

The company has completed major expansions including a dedicated Oncology Formulation Plant at Haridwar and capacity expansion at the Bhiwadi plant. Future growth is expected to be supported by the absence of major debt-funded capex, focusing instead on modernization of the Bhiwadi plant to meet EU standards.

Credit Rating & Borrowing

CRISIL reaffirmed ratings at 'BBB-/Stable' for long-term and 'A3' for short-term facilities. Interest coverage remains robust at 5.59x to 6.18x, though it declined from 7.90x in FY23 due to lower operating profits.

⚙️ Operational Drivers

Raw Materials

Formulations are based on Betalactum and Non-Betalactum drug bases. Specific API names are not disclosed, but these chemical bases represent the primary input cost for the company's tablet, capsule, and injection lines.

Import Sources

Not specifically disclosed in the documents, though the company operates manufacturing facilities in Bhiwadi (Rajasthan) and Haridwar (Uttarakhand).

Capacity Expansion

Current operations include a US-FDA approved Oncology plant in Haridwar and an EU GMP (Greece) approved Bhiwadi plant. The company is currently modernizing the Bhiwadi facility to maintain EU compatibility and has applied for desktop approval in Australia.

Raw Material Costs

Not disclosed as a specific percentage of revenue, but the company manages commodity price risk and foreign exchange risk through its Risk Management Committee to mitigate input cost volatility.

Manufacturing Efficiency

Efficiency is currently impacted by the oncology segment's sub-optimal utilization. Breakeven in this segment is the primary target for FY25 to restore group-level manufacturing efficiency.

Logistics & Distribution

The company launched Medicamen Lifesciences, a subsidiary with a team of 110 personnel, specifically to handle domestic distribution and marketing for Cardio-Vascular, diabetic, and pain management products.

📈 Strategic Growth

Expected Growth Rate

11-15%

Growth Strategy

Growth will be achieved by scaling the oncology segment to breakeven in FY25, entering the US market following US-FDA approval, and expanding the domestic footprint through the Medicamen Lifesciences subsidiary. The company has already filed its first ANDA with the US-FDA for Bortezomib injection (3.5mg).

Products & Services

Oncology formulations (including Bortezomib injections), Betalactum and Non-Betalactum drugs, Cardio-Vascular (CVD) medications, diabetic treatments, and pain management products.

Brand Portfolio

Medicamen, Medicamen Lifesciences (subsidiary), Shivalik Rasayan Ltd (Promoter Group).

New Products/Services

New product launches are focused on the Cardio-Vascular and Diabetic (CVD) segments and Pain Management through the new domestic distribution team.

Market Expansion

Targeting entry into the USA and European countries over the medium term. Currently seeking desktop approval in Australia and leveraging existing EU GMP certification for Bhiwadi.

Strategic Alliances

The company is 41.6% owned by Shivalik Rasayan Ltd, which provides strong promoter backing and industry linkages.

🌍 External Factors

Industry Trends

The pharmaceutical industry is shifting toward specialized oncology and chronic therapies (CVD/Diabetes). Medicamen is positioning itself by moving from general formulations to US-FDA approved oncology manufacturing.

Competitive Landscape

Competes with other formulation manufacturers in the domestic government tender business and international generic players in the African market.

Competitive Moat

The company's moat is built on its 30-year track record, US-FDA/EU GMP certified facilities, and a specialized oncology plant which acts as a high-entry-barrier asset.

Macro Economic Sensitivity

Highly sensitive to African economic stability and shipping logistics, as 70% of revenue is tied to this geography.

Consumer Behavior

Increasing demand for affordable oncology and chronic disease treatments in emerging markets (Africa) and regulated markets (USA/EU).

Geopolitical Risks

Trade barriers or shipping disruptions in the Africa-India corridor represent a major risk to the 70% revenue base.

⚖️ Regulatory & Governance

Industry Regulations

Operations are strictly governed by US-FDA standards for the Haridwar plant and EU GMP standards for the Bhiwadi plant. Compliance with SEBI Listing Regulations and the Companies Act 2013 is maintained for corporate governance.

Environmental Compliance

The Risk Management Committee is tasked with overseeing ESG-related risks and sustainability frameworks.

Taxation Policy Impact

Not specifically disclosed, but the company maintains a 10% dividend payout policy relative to paid-up capital.

Legal Contingencies

No specific pending court cases or case values in INR were disclosed in the provided documents.

⚠️ Risk Analysis

Key Uncertainties

The primary uncertainty is the timeline for the oncology segment to reach full capacity and breakeven, which currently impacts group margins by approximately 5%.

Geographic Concentration Risk

High concentration risk with 70% of revenue derived from Africa.

Third Party Dependencies

Dependency on shipping lines for African exports is a critical bottleneck, causing GCA to stretch to 357 days.

Technology Obsolescence Risk

The company is mitigating technology risk by modernizing its Bhiwadi plant to meet evolving EU standards.

Credit & Counterparty Risk

Receivables are generally secured by Letters of Credit for international sales, reducing the risk of bad debts despite the long 103-day collection cycle.